Obesity increases the risk of diabetes up to 90-fold and worsens hyperglycemia, hyperinsulinemia, insulin resistance, dyslipidemia, and nonalcoholic fatty liver disease. For patients with type 2 diabetes, weight loss can trigger improvements in all these conditions and decrease the need for glucose-lowering agents. The incretin mimetic exenatide shares many glucoregulatory properties with native glucagon-like peptide-1, including enhancement of glucose-dependent insulin secretion, glucose-dependent suppression of inappropriately high glucagon secretion, slowing of gastric emptying, and reduction of food intake in patients with type 2 diabetes. Exenatide treatment was associated with progressive weight loss in the majority of patients in clinical trials. In addition, patients with elevated markers of liver injury at baseline showed improvements. Therefore, exenatide represents a unique option for adjunctive therapy for patients with type 2 diabetes not achieving adequate glycemic control on oral antidiabetic agents, especially in patients for whom weight gain would be an additional contraindication.
AndersonJWKendallCWJenkinsDJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003; 22 (5): 331–9.
2.
MaggioCAPi-SunyerFX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am. 2003; 32 (4): 805–22.
3.
SteinCJColditzGA. The epidemic of obesity. J Clin Endocrinol Metab. 2004; 89 (6): 2522–5.
4.
MokdadAHFordESBowmanBANelsonDEEngelgauMMVinicorFMarksJS. Diabetes trends in the U.S.: 1990–1998. Diabetes Care. 2000; 23 (9): 1278–83.
5.
MokdadAHFordESBowmanBADietzWHVinicorFBalesVSMarksJS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003; 289 (1): 76–9.
6.
BrayGA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004; 89 (6): 2583–9.
7.
Yki-JärvinenHWesterbackaJ. The fatty liver and insulin resistance. Curr Mol Med. 2005; 5 (3): 287–95.
8.
BuseJBGinsbergHNBakrisGLClarkNGCostaFEckelRFonsecaVGersteinHCGrundySNestoRWPignoneMPPlutzkyJPorteDRedbergRStitzelKFStoneNJ. Primary prevention of cardiovascular diseases in people with diabetes mellitus. Diabetes Care. 2007; 30 (1): 162–72.
9.
StonehouseAHMaggsDG. Emerging therapies for type 2 diabetes. Curr Drug Ther. 2007; 2: 151–60.
10.
U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995; 44 (11): 1249–58.
11.
PurnellJQWeyerC. Weight effect of current and experimental drugs for diabetes mellitus: from prevention to alleviation of obesity. Treat Endocrinol. 2003; 2 (1): 33–47.
12.
WilliamsonDFThompsonTJThunMFlandersDPamukEByersT. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care. 2000; 23 (10): 1499–504.
13.
American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology. 2002; 123 (5): 1702–4.
14.
RazIEldorRCerneaSShafrirE. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev. 2005; 21 (1): 3–14.
15.
TargherGBertoliniLPadovaniRRodellaSTessariRZenariLDayCArcaroG. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007; 30 (5): 1212–8.
16.
EngJKleinmanWASinghLSinghGRaufmanJP. Isolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992; 267 (11): 7402–5.
17.
YoungAA. Glucagon-like peptide-1, exendin and insulin sensitivity. In: HansenBShafrirE, editors. Insulin resistance and insulin resistance syndrome. New York: Harwood Academic Press; 2002. p. 235–62.
18.
ParkesDGPittnerRJodkaCSmithPYoungA. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.Metabolism. 2001; 50 (5): 583–9.
19.
WebbDMWintleMMaloneJK. Exenatide effects on glucose metabolism and metabolic disorders common to overweight and obese patients with type 2 diabetes. Drug Dev Res. 2006; 67 (8): 666–76.
20.
NauckMADuranSKimDJohnsDNorthrupJFestaABrodowsRTrautmannM. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007; 50 (2): 259–67.
21.
ZinmanBHoogwerfBJGarciaSDMiltonDRGiaconiaJMKimDDTrautmannMEBrodowsRG. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med. 2007; 146 (7): 477–85.
22.
MackCLaugeroKLiuQJodkaCYoungAParkesD. Therapeutic applications of incretin mimetics for metabolic diseases: preclinical studies. Drug Dev Res. 2006; 67 (7): 553–8.
23.
ChenYEDruckerDJ. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem. 1997; 272 (7): 4108–15.
24.
KoltermanOGKimDDShenLRugglesJANielsenLLFinemanMSBaronAD. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005; 62 (2): 173–81.
25.
FehseFTrautmannMHolstJJHalsethAENanayakkaraNNielsenLLFinemanMSKimDDNauckMA. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocr Metab. 2005; 90 (11): 5991–7.
26.
NielsenLLYoungAAParkesD. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004; 117 (2): 77–88.
27.
BuseJBHenryRRHanJKimDDFinemanMSBaronAD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27 (11): 2628–35.
28.
DeFronzoRARatnerREHanJKimDDFinemanMSBaronAD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28 (5): 1092–100.
29.
KendallDMRiddleMCRosenstockJZhuangDKimDDFinemanMSBaronAD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28 (5): 1083–91.
30.
BlondeLKleinEJHanJZhangBMacSMPoonTHTaylorKLTrautmannMEKimDDKendallDM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006; 8 (4): 436–47.
31.
BuseJBKlonoffDCNielsenLLGuanXBowlusCLHolcombeJHMaggsDGWintleME. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007; 29 (1): 139–53.
32.
KlonoffDCBuseJBNielsenLLGuanXBowlusCLHolcombeJHWintleMEMaggsDG. Exenatide effects on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008; 24 (1): 275–86.
33.
TushuizenMEBunckMCPouwelsPJvan WaesbergheJHDiamantMHeineRJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int. 2006; 26 (8): 1015–7.
34.
DingXSaxenaNKLinSGuptaNAnaniaFA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology. 2006; 43 (1): 173–81.
35.
HeineRJVan GaalLFJohnsDMihmMJWidelMHBrodowsRG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med. 143 (8): 559–569.
36.
KimDMacConellLZhuangDKotharePATrautmannMFinemanMTaylorK. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007; 30 (6): 1487–93.
37.
NelsonPPoonTGuanXSchnabelCAWintleMFinemanM. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther. 2007; 9 (4): 317–26.
